Key Drivers
- Gross Margin
- Cash Burn
- Rising Leverage
AIAI Summary
WGS is now a cash-conversion story, not a volume-growth story: despite strong exome/genome demand and attractive ~68%–70% gross margins, the stock is only investable if management quickly fixes weak collections and contains the Fabric-related legal overhang before negative free cash flow and rising debt erode the gains.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Rising Leverage
WGS has strong gross margins and positive annual cash flow, but widening losses, a sharp quarterly cash burn, and rising leverage make the near-term investment case increasingly risky.
Price Behavior
Key Price Behavior Insights:
- •Breakout momentum
- •Overextension risk
- •Support holding
WGS has a strong short-term uptrend over the last month after breaking above $63-$65 and rallying to $82.39, but it looks overextended and needs to hold $77-$78 to avoid a deeper pullback.
Fast rally from the $63-$65 breakout zone to $82.39 signals elevated pullback risk
Sentiment & News
Key News Insights:
- •Lead plaintiff deadline
- •Acquisition dispute
- •Stock pressure
GeneDx is facing intensified shareholder litigation scrutiny over alleged misstatements tied to the Fabric Genomics acquisition and its unrealized synergy expectations.
The ongoing legal overhang could keep WGS under pressure and weigh on investor sentiment until the class action timeline clears
Similar Companies in Healthcare
Other companies in the same sector with AI ratings